Search
Arcturus Therapeutics Holdings Inc
ARCTAdd to Watchlist
7.470USD
-0.360-4.60%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
212.32MMarket Cap
LossP/E TTM
View Detailed Chart
Intraday
1m
30m
1h
D
W
M
D
Today
-4.60%
5 Days
-18.98%
1 Month
-15.50%
6 Months
+2.75%
Year to Date
+21.86%
1 Year
-35.88%
TradingKey Stock Score of Arcturus Therapeutics Holdings Inc
Currency: USD Updated: 2026-05-15Key Insights
Arcturus Therapeutics Holdings Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 116 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 23.00.In the medium term, the stock price is expected to remain stable.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Arcturus Therapeutics Holdings Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Arcturus Therapeutics Holdings Inc Highlights
StrengthsRisks
Arcturus Therapeutics Holdings Inc. is a commercial mRNA medicines and vaccines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. The Company with enabling technologies, including LUNAR lipid-mediated delivery, STARR mRNA technology (sa-mRNA) and mRNA drug substances along with drug product manufacturing. It has developed KOSTAIVE, a self-amplifying messenger RNA (sa-mRNA) COVID vaccine. The Company’s pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. The Company's versatile RNA therapeutics platforms can be applied to multiple types of nucleic acid medicines, including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics.
Growing
The company is in a growing phase, with the latest annual income totaling USD 82.03M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 82.03M.
Overvalued
The company’s latest PE is -2.64, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 23.00M shares, decreasing 21.86% quarter-over-quarter.
Held by Invesco
Star Investor Invesco holds 99.88K shares of this stock.
Analyst Rating
Based on
12
analysts
Buy
Current Rating
23.000
Target Price
+193.74%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Arcturus Therapeutics Holdings Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Arcturus Therapeutics Holdings Inc Info
Arcturus Therapeutics Holdings Inc. is a commercial mRNA medicines and vaccines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. The Company with enabling technologies, including LUNAR lipid-mediated delivery, STARR mRNA technology (sa-mRNA) and mRNA drug substances along with drug product manufacturing. It has developed KOSTAIVE, a self-amplifying messenger RNA (sa-mRNA) COVID vaccine. The Company’s pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. The Company's versatile RNA therapeutics platforms can be applied to multiple types of nucleic acid medicines, including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics.
Ticker SymbolARCT
CompanyArcturus Therapeutics Holdings Inc
CEOPayne (Joseph E)
Websitehttps://arcturusrx.com/
Related Instruments
-0.03%
-1.75%
-0.15%
-1.11%
-1.77%
-1.79%
-2.22%
-1.88%
-2.35%
-1.63%
+0.43%
-2.99%
-0.37%
-1.64%
+1.79%
0.00%
-2.05%
-0.15%
-2.77%
+0.41%Popular Instruments
102.160
+3.297 (+3.33%)
300.230
+2.020 (+0.68%)
225.320
-10.420 (-4.42%)
4538.710
-111.520 (-2.40%)
482.020
-7.101 (-1.45%)
1407.610
+24.890 (+1.80%)
724.660
-51.350 (-6.62%)
396.780
-4.290 (-1.07%)
78085.600
-145.400 (-0.19%)
422.240
-21.060 (-4.75%)
